On July 13, 2026, Major Pharmaceuticals recalled certain lots of several strengths of its Levothyroxine Sodium Tablets, USP, a generic thyroid medication, because the tablets may be subpotent. FDA classified the recall as Class II, indicating that use of the products may cause temporary or medically reversible health problems.

Levothyroxine is a prescription thyroid hormone medication used to treat hypothyroidism. Because the recalled tablets may be subpotent, patients using recalled lots may not receive the full labeled dose. Patients taking recalled Levothyroxine Sodium Tablets, USP should contact their pharmacist or healthcare provider for guidance and should not stop taking prescribed thyroid medication without medical advice.

You can learn more about generic versions of levothyroxine in ConsumerLab’s article about levothyroxine (Synthroid) and supplements. Also see our article All About Thyroid Supplements & Desiccated Thyroid Extract (Armour Thyroid).

The recalled products were distributed nationwide in the U.S. and can be identified as follows:

Levothyroxine Sodium Tablets, USP, 25 mcg, 100 tablets, NDC 0904-6949-61
Lot: N02212, Exp. 07/2026

Levothyroxine Sodium Tablets, USP, 50 mcg, 100 tablets, NDC 0904-6950-61
Lot: N02200, Exp. 10/2026

Levothyroxine Sodium Tablets, USP, 75 mcg, 100 tablets, NDC 0904-6951-61
Lots: N02172, Exp. 07/2026; N02296, Exp. 12/2026; N02288, Exp. 12/2026

Levothyroxine Sodium Tablets, USP, 88 mcg, 100 tablets, NDC 0904-6952-61
Lot: N02310, Exp. 01/2027

Levothyroxine Sodium Tablets, USP, 112 mcg, 100 tablets, NDC 0904-6954-61
Lot: N02203, Exp. 09/2026

Levothyroxine Sodium Tablets, USP, 125 mcg, 100 tablets, NDC 0904-6955-61
Lot: N02266, Exp. 11/2026

Levothyroxine Sodium Tablets, USP, 150 mcg, 100 tablets, NDC 0904-6956-61
Lot: N02167, Exp. 07/2026

The recall also includes certain 10-tablet unit-dose blister cartons distributed by Cardinal Health:

Levothyroxine Sodium Tablets, USP, 25 mcg, 10 tablets, NDC carton 55154-3558-0; NDC blister 0904-6949-61
Bag lots: N02212A, N02212B, Exp. 07/2026; Blister lot: N02212, Exp. 07/2026

Levothyroxine Sodium Tablets, USP, 50 mcg, 10 tablets, NDC bag 55154-3559-0; NDC blister 0904-6950-61
Bag lots: N02200A, N02200B, Exp. 10/2026; Blister lot: N02200, Exp. 10/2026

Levothyroxine Sodium Tablets, USP, 75 mcg, 10 tablets, NDC bag 55154-3560-0; NDC blister 0904-6951-61
Bag lots: N02172A, N02172B, Exp. 07/2026; N02288A, N02288B, Exp. 12/2026; Blister lots: N02172, Exp. 07/2026; N02288, Exp. 12/2026

Levothyroxine Sodium Tablets, USP, 125 mcg, 10 tablets, NDC bag 55154-3562-0; NDC blister 0904-6955-61
Bag lots: N02266A, N02266B, Exp. 11/2026; Blister lot: N02266, Exp. 11/2026

Levothyroxine Sodium Tablets, USP, 150 mcg, 10 tablets, NDC bag 55154-3563-0; NDC blister 0904-6956-61
Bag lot: N02167A, Exp. 07/2026; Blister lot: N02167, Exp. 07/2026

FDA’s Enforcement Report lists the recall status as ongoing and notes that no press release was issued for this recall.

For more information, use the link below.

FDA Enforcement Report: Major Pharmaceuticals Levothyroxine Sodium Tablets Recall

See related recalls and warnings:

Thyroid Supplement Recalled Due to Salmonella